CRON vs. VKTX, MTSR, AKRO, ALVO, CPRX, CRNX, SRRK, MRUS, MOR, and PTGX
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Viking Therapeutics (VKTX), Metsera (MTSR), Akero Therapeutics (AKRO), Alvotech (ALVO), Catalyst Pharmaceuticals (CPRX), Crinetics Pharmaceuticals (CRNX), Scholar Rock (SRRK), Merus (MRUS), MorphoSys (MOR), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.
Cronos Group vs.
Viking Therapeutics (NASDAQ:VKTX) and Cronos Group (NASDAQ:CRON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, earnings and profitability.
Viking Therapeutics received 171 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 80.08% of users gave Viking Therapeutics an outperform vote while only 61.13% of users gave Cronos Group an outperform vote.
Viking Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.06, meaning that its stock price is 6% more volatile than the S&P 500.
Viking Therapeutics has a net margin of 0.00% compared to Cronos Group's net margin of -42.65%. Cronos Group's return on equity of -2.56% beat Viking Therapeutics' return on equity.
Viking Therapeutics currently has a consensus target price of $87.15, suggesting a potential upside of 223.03%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Viking Therapeutics is more favorable than Cronos Group.
Cronos Group has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Cronos Group shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by company insiders. Comparatively, 7.3% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
In the previous week, Viking Therapeutics had 12 more articles in the media than Cronos Group. MarketBeat recorded 14 mentions for Viking Therapeutics and 2 mentions for Cronos Group. Viking Therapeutics' average media sentiment score of 1.54 beat Cronos Group's score of 0.96 indicating that Viking Therapeutics is being referred to more favorably in the media.
Summary
Viking Therapeutics beats Cronos Group on 10 of the 18 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
This page (NASDAQ:CRON) was last updated on 5/25/2025 by MarketBeat.com Staff
